Bionomics CEO Buys $45.7K in Stock, Signals Undervaluation
Ticker: NEUP · Form: 6-K · Filed: Jan 4, 2024 · CIK: 1191070
| Field | Detail |
|---|---|
| Company | Bionomics Limited/Fi (NEUP) |
| Form Type | 6-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $45,682 |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: insider-buy, CEO-confidence, undervaluation, pharmaceuticals
TL;DR
**Bionomics CEO just bought $45,682 of BNOX stock, signaling strong confidence and potential undervaluation.**
AI Summary
Bionomics Limited (NASDAQ: BNOX) CEO, Spyros Papapetropoulos, recently purchased 33,333 American Depositary Shares (ADS) for an aggregate price of $45,682 on the open market. This significant insider buying signals his strong confidence in the company's future and his belief that the current stock valuation is undervalued. For investors, this matters because a CEO's personal investment often indicates a positive outlook and commitment to driving shareholder value, potentially signaling future growth.
Why It Matters
This insider purchase by the CEO suggests he believes Bionomics' stock is currently undervalued and has significant growth potential, which could be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — A CEO buying shares on the open market is generally a positive signal, indicating confidence in the company's future prospects and potentially reduced risk.
Analyst Insight
A smart investor would view this insider buying as a strong vote of confidence from the CEO, potentially indicating that the stock is undervalued. It might warrant further research into Bionomics' fundamentals and future prospects, and potentially considering an investment.
Key Numbers
- 33,333 — ADS purchased (number of American Depositary Shares acquired by the CEO)
- $45,682 — Aggregate Purchase Price (total amount spent by the CEO on the stock purchase)
Key Players & Entities
- Bionomics Limited (company) — the registrant and company whose stock was purchased
- Spyros Papapetropoulos (person) — CEO of Bionomics Limited who purchased shares
- $45,682 (dollar_amount) — aggregate purchase price of the shares
- NASDAQ (company) — stock exchange where Bionomics' securities are traded
Forward-Looking Statements
- Bionomics Limited's stock price will see an upward trend in the short to medium term. (Bionomics Limited) — medium confidence, target: 6 months
- The company's management will continue to demonstrate strong confidence in its valuation. (Bionomics Limited) — high confidence, target: 12 months
FAQ
Who purchased the Bionomics Limited (NASDAQ: BNOX) shares mentioned in this filing?
The CEO of Bionomics Limited, Spyros Papapetropoulos, purchased the shares.
How many American Depositary Shares (ADS) did the CEO acquire?
The CEO acquired a total of 33,333 ADS.
What was the aggregate purchase price for these shares?
The aggregate purchase price for the 33,333 ADS was $45,682.
Where were these shares purchased?
The shares were acquired in the open market.
What is the CEO's stated intention regarding future share acquisitions?
The CEO intends to consistently acquire additional shares of the Company in the future, in accordance with the Company’s Securities Trading Policy and applicable law.
Filing Stats: 337 words · 1 min read · ~1 pages · Grade level 15.5 · Accepted 2024-01-04 06:04:07
Key Financial Figures
- $45,682 — reflects an aggregate purchase price of $45,682, acquired in the open market, demonstra
Filing Documents
- bnox-6k-ceoacquiresshare.htm (6-K) — 22KB
- 0000950170-24-001476.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. Bionomics Limited (Registrant) By: /s/ Alan Fisher Name: Alan Fisher Title: Chairman of the Board Date: January 04, 2024 1